Genzyme’s Cerdelga receives European approval to treat Gaucher disease type 1

Sanofi subsidiary Genzyme has received marketing approval from European Commission (EC) for its Cerdelga (eliglustat) capsules to treat adult patients with Gaucher disease type 1.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news